v3.26.1

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 25,661	$ 28,492
Investments	112,558	134,777
Restricted cash	385	670
Prepaid expenses and other current assets	4,962	3,015
Total current assets	143,566	166,954
Property and equipment, net	116	159
Operating lease right-of-use assets	798	1,082
Total assets	144,480	168,195
Current liabilities:
Accounts payable	435	2,215
Accrued expenses	16,498	16,844
Operating lease liabilities	1,205	1,633
Total current liabilities	18,138	20,692
Total liabilities	18,138	20,692
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2026 and December 31, 2025	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized, 17,738,870 and 17,611,511 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	2	2
Additional paid-in capital	704,900	702,984
Accumulated deficit	(578,399)	(555,430)
Accumulated other comprehensive loss	(161)	(53)
Total stockholders’ equity	126,342	147,503
Total liabilities and stockholders’ equity	$ 144,480	$ 168,195

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Corbus Pharmaceuticals Holdings, Inc. 10-Q